<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nature</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
        <journal-id journal-id-type="pmc-domain-id">981</journal-id>
        <journal-id journal-id-type="pmc-domain">npgopen</journal-id>
        <journal-title-group>
          <journal-title>Nature</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0028-0836</issn>
        <issn pub-type="epub">1476-4687</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>Nature Portfolio</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC3704730</article-id>
        <article-id pub-id-type="pmcid-ver">PMC3704730.2</article-id>
        <article-id pub-id-type="pmcaid">3704730</article-id>
        <article-id pub-id-type="pmcaiid">7449520</article-id>
        <article-id pub-id-type="pmid">23636398</article-id>
        <article-id pub-id-type="doi">10.1038/nature12113</article-id>
        <article-id pub-id-type="publisher-id">BFnature12113</article-id>
        <article-version article-version-type="pmc-version">2</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Integrated genomic characterization of endometrial carcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Levine</surname>
              <given-names initials="DA">Douglas A.</given-names>
            </name>
            <address>
              <email>levine2@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff51">51</xref>
          </contrib>
          <contrib contrib-type="author">
            <collab>The Cancer Genome Atlas Research Network<contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Getz</surname><given-names initials="G">Gad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gabriel</surname><given-names initials="SB">Stacey B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cibulskis</surname><given-names initials="K">Kristian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lander</surname><given-names initials="E">Eric</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sivachenko</surname><given-names initials="A">Andrey</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sougnez</surname><given-names initials="C">Carrie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lawrence</surname><given-names initials="M">Mike</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><on-behalf-of>for the Genome sequencing centres: Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kandoth</surname><given-names initials="C">Cyriac</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dooling</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fulton</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fulton</surname><given-names initials="L">Lucinda</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kalicki-Veizer</surname><given-names initials="J">Joelle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McLellan</surname><given-names initials="MD">Michael D.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>O’Laughlin</surname><given-names initials="M">Michelle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schmidt</surname><given-names initials="H">Heather</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wilson</surname><given-names initials="RK">Richard K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ye</surname><given-names initials="K">Kai</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="L">Li</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mardis</surname><given-names initials="ER">Elaine R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><on-behalf-of>for the Washington University in St Louis</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ally</surname><given-names initials="A">Adrian</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balasundaram</surname><given-names initials="M">Miruna</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Birol</surname><given-names initials="I">Inanc</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Butterfield</surname><given-names initials="YSN">Yaron S. N.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carlsen</surname><given-names initials="R">Rebecca</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carter</surname><given-names initials="C">Candace</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="A">Andy</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chuah</surname><given-names initials="E">Eric</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chun</surname><given-names initials="HJE">Hye-Jung E.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhalla</surname><given-names initials="N">Noreen</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guin</surname><given-names initials="R">Ranabir</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hirst</surname><given-names initials="C">Carrie</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Holt</surname><given-names initials="RA">Robert A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="SJM">Steven J. M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="D">Darlene</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="HI">Haiyan I.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marra</surname><given-names initials="MA">Marco A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mayo</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moore</surname><given-names initials="RA">Richard A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mungall</surname><given-names initials="AJ">Andrew J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Plettner</surname><given-names initials="P">Patrick</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schein</surname><given-names initials="JE">Jacqueline E.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sipahimalani</surname><given-names initials="P">Payal</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tam</surname><given-names initials="A">Angela</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Varhol</surname><given-names initials="RJ">Richard J.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon Robertson</surname><given-names initials="A">A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><on-behalf-of>for the Genome characterization centres: British Columbia Cancer Agency</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cherniack</surname><given-names initials="AD">Andrew D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pashtan</surname><given-names initials="I">Itai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saksena</surname><given-names initials="G">Gordon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onofrio</surname><given-names initials="RC">Robert C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schumacher</surname><given-names initials="SE">Steven E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tabak</surname><given-names initials="B">Barbara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carter</surname><given-names initials="SL">Scott L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hernandez</surname><given-names initials="B">Bryan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gentry</surname><given-names initials="J">Jeff</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salvesen</surname><given-names initials="HB">Helga B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ardlie</surname><given-names initials="K">Kristin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Getz</surname><given-names initials="G">Gad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winckler</surname><given-names initials="W">Wendy</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beroukhim</surname><given-names initials="R">Rameen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gabriel</surname><given-names initials="SB">Stacey B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meyerson</surname><given-names initials="M">Matthew</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><on-behalf-of>for the Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hadjipanayis</surname><given-names initials="A">Angela</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="S">Semin</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahadeshwar</surname><given-names initials="HS">Harshad S.</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="P">Peter</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Protopopov</surname><given-names initials="A">Alexei</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ren</surname><given-names initials="X">Xiaojia</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seth</surname><given-names initials="S">Sahil</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="X">Xingzhi</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="J">Jiabin</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xi</surname><given-names initials="R">Ruibin</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="L">Lixing</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="D">Dong</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kucherlapati</surname><given-names initials="R">Raju</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chin</surname><given-names initials="L">Lynda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jianhua</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><on-behalf-of>for the Harvard Medical School/Brigham &amp; Women’s Hospital/MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Todd Auman</surname><given-names initials="J">J.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balu</surname><given-names initials="S">Saianand</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bodenheimer</surname><given-names initials="T">Tom</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buda</surname><given-names initials="E">Elizabeth</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neil Hayes</surname><given-names initials="D">D.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoyle</surname><given-names initials="AP">Alan P.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jefferys</surname><given-names initials="SR">Stuart R.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="CD">Corbin D.</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="S">Shaowu</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mieczkowski</surname><given-names initials="PA">Piotr A.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mose</surname><given-names initials="LE">Lisle E.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parker</surname><given-names initials="JS">Joel S.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perou</surname><given-names initials="CM">Charles M.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roach</surname><given-names initials="J">Jeff</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="Y">Yan</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simons</surname><given-names initials="JV">Janae V.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soloway</surname><given-names initials="MG">Mathew G.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tan</surname><given-names initials="D">Donghui</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Topal</surname><given-names initials="MD">Michael D.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Waring</surname><given-names initials="S">Scot</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="J">Junyuan</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoadley</surname><given-names initials="KA">Katherine A.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><on-behalf-of>for the University of North Carolina</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Baylin</surname><given-names initials="SB">Stephen B.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bootwalla</surname><given-names initials="MS">Moiz S.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lai</surname><given-names initials="PH">Phillip H.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Triche Jr</surname><given-names initials="TJ">Timothy J.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van Den Berg</surname><given-names initials="DJ">David J.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weisenberger</surname><given-names initials="DJ">Daniel J.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laird</surname><given-names initials="PW">Peter W.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="H">Hui</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><on-behalf-of>for the University of Southern California &amp; Johns Hopkins</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chin</surname><given-names initials="L">Lynda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jianhua</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Getz</surname><given-names initials="G">Gad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cho</surname><given-names initials="J">Juok</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DiCara</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frazer</surname><given-names initials="S">Scott</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heiman</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jing</surname><given-names initials="R">Rui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="P">Pei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallard</surname><given-names initials="W">Will</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stojanov</surname><given-names initials="P">Petar</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Voet</surname><given-names initials="D">Doug</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="H">Hailei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zou</surname><given-names initials="L">Lihua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noble</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lawrence</surname><given-names initials="M">Mike</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><on-behalf-of>for the Genome data analysis centres: Broad Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Reynolds</surname><given-names initials="SM">Sheila M.</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shmulevich</surname><given-names initials="I">Ilya</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><on-behalf-of>for the Institute for Systems Biology</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Arman Aksoy</surname><given-names initials="B">B.</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Antipin</surname><given-names initials="Y">Yevgeniy</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ciriello</surname><given-names initials="G">Giovanni</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dresdner</surname><given-names initials="G">Gideon</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="J">Jianjiong</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gross</surname><given-names initials="B">Benjamin</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names initials="A">Anders</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ladanyi</surname><given-names initials="M">Marc</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reva</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sander</surname><given-names initials="C">Chris</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sinha</surname><given-names initials="R">Rileen</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Onur Sumer</surname><given-names initials="S">S.</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="BS">Barry S.</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cerami</surname><given-names initials="E">Ethan</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinhold</surname><given-names initials="N">Nils</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="N">Nikolaus</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="R">Ronglai</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><on-behalf-of>for the Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Benz</surname><given-names initials="S">Stephen</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goldstein</surname><given-names initials="T">Ted</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haussler</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ng</surname><given-names initials="S">Sam</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Szeto</surname><given-names initials="C">Christopher</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stuart</surname><given-names initials="J">Joshua</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benz</surname><given-names initials="CC">Christopher C.</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yau</surname><given-names initials="C">Christina</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><on-behalf-of>for the University of California, Santa Cruz/Buck Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Annala</surname><given-names initials="M">Matti</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broom</surname><given-names initials="BM">Bradley M.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Casasent</surname><given-names initials="TD">Tod D.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ju</surname><given-names initials="Z">Zhenlin</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="H">Han</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="G">Guoyan</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="Y">Yiling</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Unruh</surname><given-names initials="AK">Anna K.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wakefield</surname><given-names initials="C">Chris</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinstein</surname><given-names initials="JN">John N.</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="N">Nianxiang</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuexin</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broaddus</surname><given-names initials="R">Russell</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akbani</surname><given-names initials="R">Rehan</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mills</surname><given-names initials="GB">Gordon B.</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><on-behalf-of>for the The University of Texas MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Adams</surname><given-names initials="C">Christopher</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barr</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Black</surname><given-names initials="AD">Aaron D.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bowen</surname><given-names initials="J">Jay</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deardurff</surname><given-names initials="J">John</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frick</surname><given-names initials="J">Jessica</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gastier-Foster</surname><given-names initials="JM">Julie M.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grossman</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harper</surname><given-names initials="HA">Hollie A.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hart-Kothari</surname><given-names initials="M">Melissa</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Helsel</surname><given-names initials="C">Carmen</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hobensack</surname><given-names initials="A">Aaron</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuck</surname><given-names initials="H">Harkness</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kneile</surname><given-names initials="K">Kelley</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leraas</surname><given-names initials="KM">Kristen M.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lichtenberg</surname><given-names initials="TM">Tara M.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McAllister</surname><given-names initials="C">Cynthia</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pyatt</surname><given-names initials="RE">Robert E.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramirez</surname><given-names initials="NC">Nilsa C.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tabler</surname><given-names initials="TR">Teresa R.</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vanhoose</surname><given-names initials="N">Nathan</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>White</surname><given-names initials="P">Peter</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wise</surname><given-names initials="L">Lisa</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zmuda</surname><given-names initials="E">Erik</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><on-behalf-of>for the Biospecimen core resource: Nationwide Children’s Hospital</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Barnabas</surname><given-names initials="N">Nandita</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Berry-Green</surname><given-names initials="C">Charlenia</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blanc</surname><given-names initials="V">Victoria</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boice</surname><given-names initials="L">Lori</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Button</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farkas</surname><given-names initials="A">Adam</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Green</surname><given-names initials="A">Alex</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>MacKenzie</surname><given-names initials="J">Jean</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nicholson</surname><given-names initials="D">Dana</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><on-behalf-of>for the Tissue source sites: Asterand</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kalloger</surname><given-names initials="SE">Steve E.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blake Gilks</surname><given-names initials="C">C.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref><xref ref-type="aff" rid="Aff40">40</xref></contrib><on-behalf-of>for the British Columbia Cancer Agency</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Karlan</surname><given-names initials="BY">Beth Y.</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lester</surname><given-names initials="J">Jenny</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Orsulic</surname><given-names initials="S">Sandra</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><on-behalf-of>for the Cedars-Sinai Medical Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Borowsky</surname><given-names initials="M">Mark</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cadungog</surname><given-names initials="M">Mark</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Czerwinski</surname><given-names initials="C">Christine</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huelsenbeck-Dill</surname><given-names initials="L">Lori</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iacocca</surname><given-names initials="M">Mary</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petrelli</surname><given-names initials="N">Nicholas</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rabeno</surname><given-names initials="B">Brenda</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Witkin</surname><given-names initials="G">Gary</given-names></name><xref ref-type="aff" rid="Aff42">42</xref></contrib><on-behalf-of>for the Christiana Care</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nemirovich-Danchenko</surname><given-names initials="E">Elena</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Potapova</surname><given-names initials="O">Olga</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rotin</surname><given-names initials="D">Daniil</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><on-behalf-of>for the Cureline</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Berchuck</surname><given-names initials="A">Andrew</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><on-behalf-of>for the Duke University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Birrer</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DiSaia</surname><given-names initials="P">Phillip</given-names></name><xref ref-type="aff" rid="Aff46">46</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Monovich</surname><given-names initials="L">Laura</given-names></name><xref ref-type="aff" rid="Aff47">47</xref></contrib><on-behalf-of>for the Gynecologic Oncology Group</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Curley</surname><given-names initials="E">Erin</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gardner</surname><given-names initials="J">Johanna</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallery</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Penny</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="Aff48">48</xref></contrib><on-behalf-of>for the International Genomics Consortium</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dowdy</surname><given-names initials="SC">Sean C.</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winterhoff</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dao</surname><given-names initials="L">Linda</given-names></name><xref ref-type="aff" rid="Aff50">50</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gostout</surname><given-names initials="B">Bobbie</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meuter</surname><given-names initials="A">Alexandra</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Teoman</surname><given-names initials="A">Attila</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><on-behalf-of>for the Mayo Clinic</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dao</surname><given-names initials="F">Fanny</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olvera</surname><given-names initials="N">Narciso</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bogomolniy</surname><given-names initials="F">Faina</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garg</surname><given-names initials="K">Karuna</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soslow</surname><given-names initials="RA">Robert A.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levine</surname><given-names initials="DA">Douglas A.</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><on-behalf-of>for the Memorial Sloan-Kettering Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Abramov</surname><given-names initials="M">Mikhail</given-names></name><xref ref-type="aff" rid="Aff53">53</xref></contrib><on-behalf-of>for the N. N. Blokhin Russian Cancer Research Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bartlett</surname><given-names initials="JMS">John M. S.</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kodeeswaran</surname><given-names initials="S">Sugy</given-names></name><xref ref-type="aff" rid="Aff54">54</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parfitt</surname><given-names initials="J">Jeremy</given-names></name><xref ref-type="aff" rid="Aff55">55</xref></contrib><on-behalf-of>for the Ontario Tumour Bank</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Moiseenko</surname><given-names initials="F">Fedor</given-names></name><xref ref-type="aff" rid="Aff56">56</xref></contrib><on-behalf-of>for the St Petersburg Academic University</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Clarke</surname><given-names initials="BA">Blaise A.</given-names></name><xref ref-type="aff" rid="Aff57">57</xref></contrib><on-behalf-of>for the University Health Network</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Goodman</surname><given-names initials="MT">Marc T.</given-names></name><xref ref-type="aff" rid="Aff58">58</xref><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carney</surname><given-names initials="ME">Michael E.</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Matsuno</surname><given-names initials="RK">Rayna K.</given-names></name><xref ref-type="aff" rid="Aff58">58</xref></contrib><on-behalf-of>for the University of Hawaii</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fisher</surname><given-names initials="J">Jennifer</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="M">Mei</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kimryn Rathmell</surname><given-names initials="W">W.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thorne</surname><given-names initials="L">Leigh</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Van Le</surname><given-names initials="L">Linda</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><on-behalf-of>for the University of North Carolina</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dhir</surname><given-names initials="R">Rajiv</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Edwards</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elishaev</surname><given-names initials="E">Esther</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zorn</surname><given-names initials="K">Kristin</given-names></name><xref ref-type="aff" rid="Aff60">60</xref></contrib><on-behalf-of>for the University of Pittsburgh</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Broaddus</surname><given-names initials="R">Russell</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><on-behalf-of>for the The University of Texas MD Anderson Cancer Center</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Goodfellow</surname><given-names initials="PJ">Paul J.</given-names></name><xref ref-type="aff" rid="Aff36">36</xref><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mutch</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff61">61</xref></contrib><on-behalf-of>for the Washington University School of Medicine</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="N">Nikolaus</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuexin</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akbani</surname><given-names initials="R">Rehan</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cherniack</surname><given-names initials="AD">Andrew D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cerami</surname><given-names initials="E">Ethan</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinhold</surname><given-names initials="N">Nils</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="H">Hui</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoadley</surname><given-names initials="KA">Katherine A.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kahn</surname><given-names initials="AB">Ari B.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bell</surname><given-names initials="DW">Daphne W.</given-names></name><xref ref-type="aff" rid="Aff63">63</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pollock</surname><given-names initials="PM">Pamela M.</given-names></name><xref ref-type="aff" rid="Aff64">64</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="C">Chen</given-names></name><xref ref-type="aff" rid="Aff65">65</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>A.Wheeler</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shinbrot</surname><given-names initials="E">Eve</given-names></name><xref ref-type="aff" rid="Aff66">66</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karlan</surname><given-names initials="BY">Beth Y.</given-names></name><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Berchuck</surname><given-names initials="A">Andrew</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dowdy</surname><given-names initials="SC">Sean C.</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Winterhoff</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="Aff49">49</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goodman</surname><given-names initials="MT">Marc T.</given-names></name><xref ref-type="aff" rid="Aff58">58</xref><xref ref-type="aff" rid="Aff59">59</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon Robertson</surname><given-names initials="A">A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beroukhim</surname><given-names initials="R">Rameen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pashtan</surname><given-names initials="I">Itai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salvesen</surname><given-names initials="HB">Helga B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laird</surname><given-names initials="PW">Peter W.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noble</surname><given-names initials="M">Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stuart</surname><given-names initials="J">Joshua</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="L">Li</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kandoth</surname><given-names initials="C">Cyriac</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blake Gilks</surname><given-names initials="C">C.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soslow</surname><given-names initials="RA">Robert A.</given-names></name><xref ref-type="aff" rid="Aff52">52</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goodfellow</surname><given-names initials="PJ">Paul J.</given-names></name><xref ref-type="aff" rid="Aff36">36</xref><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mutch</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff61">61</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Broaddus</surname><given-names initials="R">Russell</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mills</surname><given-names initials="GB">Gordon B.</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kucherlapati</surname><given-names initials="R">Raju</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mardis</surname><given-names initials="ER">Elaine R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levine</surname><given-names initials="DA">Douglas A.</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><on-behalf-of>for the Disease analysis working group</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ayala</surname><given-names initials="B">Brenda</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="AL">Anna L.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jensen</surname><given-names initials="MA">Mark A.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kothiyal</surname><given-names initials="P">Prachi</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pihl</surname><given-names initials="TD">Todd D.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pontius</surname><given-names initials="J">Joan</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pot</surname><given-names initials="DA">David A.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Snyder</surname><given-names initials="EE">Eric E.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names initials="D">Deepak</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kahn</surname><given-names initials="AB">Ari B.</given-names></name><xref ref-type="aff" rid="Aff62">62</xref></contrib><on-behalf-of>for the Data coordination centre</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Mills Shaw</surname><given-names initials="KR">Kenna R.</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sheth</surname><given-names initials="M">Margi</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davidsen</surname><given-names initials="T">Tanja</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eley Martin L. Ferguson</surname><given-names initials="G">Greg</given-names></name><xref ref-type="aff" rid="Aff68">68</xref><xref ref-type="aff" rid="Aff69">69</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Demchok</surname><given-names initials="JA">John A.</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="L">Liming</given-names></name><xref ref-type="aff" rid="Aff67">67</xref></contrib><on-behalf-of>for the Project team: National Cancer Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guyer</surname><given-names initials="MS">Mark S.</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozenberger</surname><given-names initials="BA">Bradley A.</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sofia</surname><given-names initials="HJ">Heidi J.</given-names></name><xref ref-type="aff" rid="Aff70">70</xref></contrib><on-behalf-of>for the National Human Genome Research Institute</on-behalf-of></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kandoth</surname><given-names initials="C">Cyriac</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schultz</surname><given-names initials="N">Nikolaus</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cherniack</surname><given-names initials="AD">Andrew D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akbani</surname><given-names initials="R">Rehan</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yuexin</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="H">Hui</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon Robertson</surname><given-names initials="A">A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pashtan</surname><given-names initials="I">Itai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="R">Ronglai</given-names></name><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benz</surname><given-names initials="CC">Christopher C.</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yau</surname><given-names initials="C">Christina</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laird</surname><given-names initials="PW">Peter W.</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="L">Li</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><xref ref-type="aff" rid="Aff30">30</xref><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mills</surname><given-names initials="GB">Gordon B.</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kucherlapati</surname><given-names initials="R">Raju</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mardis</surname><given-names initials="ER">Elaine R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levine</surname><given-names initials="DA">Douglas A.</given-names></name><xref ref-type="aff" rid="Aff51">51</xref></contrib><on-behalf-of>for the Writing committee</on-behalf-of></contrib-group></collab>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.66859.34</institution-id><institution>The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution>The Genome Institute, Washington University, St Louis, </institution></institution-wrap>Missouri, 63108 USA </aff>
          <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.248762.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0702 3000</institution-id><institution>Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Department of Radiation Oncology, </institution><institution>Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, Massachusetts 02115, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.412008.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9753 1393</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Haukeland University Hospital, 5021 Bergen, Norway., </institution></institution-wrap>, </aff>
          <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.7914.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7443</institution-id><institution>Department of Clinical Medicine, </institution><institution>University of Bergen, </institution></institution-wrap>5020 Bergen Norway </aff>
          <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Department of Medical Oncology, </institution><institution>Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Genetics, </institution><institution>Harvard Medical School, Boston, Massachusetts 02115, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts 02115, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Genomic Medicine, </institution><institution>Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Informatics Program, Boston Children’s Hospital, Boston, Massachusetts 02115, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Institute for Pharmacogenetics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Internal Medicine, Division of Medical Oncology, </institution><institution>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Biology, </institution><institution>University of North Carolina at Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Genetics, </institution><institution>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Research Computing Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.469474.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 8617 4175</institution-id><institution>Cancer Biology Division, </institution><institution>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution>University of Southern California Epigenome Center, University of Southern California, Los Angeles, California 90089, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.64212.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0463 2320</institution-id><institution>Institute for Systems Biology, Seattle, Washington 98109, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Epidemiology and Biostatistics, </institution><institution>Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.205975.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0740 6917</institution-id><institution>Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, </institution><institution>University of California Santa Cruz, Santa Cruz, California 95064, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.272799.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 8687 5377</institution-id><institution>Buck Institute for Age Research, Novato, California 94945, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Cancer Genomics Core Laboratory, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Pathology, </institution><institution>University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.502801.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2314 6254</institution-id><institution>Tampere University of Technology Korkeakoulunkatu 10, FI-33720 Tampere, Finland., </institution></institution-wrap>, </aff>
          <aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Bioinformatics and Computational Biology, </institution><institution>The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Systems Biology, </institution><institution>The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.240344.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0392 3476</institution-id><institution>The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43205, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="GRID">grid.261331.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2285 7943</institution-id><institution>The Ohio State University, Columbus, Ohio 43210, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff37"><label>37</label>Asterand, Detroit, Michigan 48202, USA., , </aff>
          <aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="GRID">grid.410711.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 1720</institution-id><institution>University of North Carolina, Chapel Hill, North Carolina 27599, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="GRID">grid.248762.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0702 3000</institution-id><institution>OvCaRe British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution>Department of Pathology &amp; Laboratory Medicine, </institution><institution>The University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="GRID">grid.50956.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2152 9905</institution-id><institution>Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="GRID">grid.414316.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 1241</institution-id><institution>Helen F Graham Cancer Center at Christiana Care, Newark, Delaware 19713, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff43"><label>43</label>Cureline, Inc., South San Francisco, California 94080, USA., , </aff>
          <aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="GRID">grid.26009.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7961</institution-id><institution>Duke University Medical Center, Duke Cancer Institute, Durham, North Carolina 27710, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff45"><label>45</label>Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA., , </aff>
          <aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="GRID">grid.413083.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9142 8600</institution-id><institution>University of California Medical Center, Irvine, Orange California 92868, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="GRID">grid.240344.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0392 3476</institution-id><institution>GOG Tissue Bank, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43205, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="GRID">grid.450294.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 0756</institution-id><institution>International Genomics Consortium, Phoenix, Arizona 85004, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Department of OB Gyn, Division of Gynecologic Oncology, </institution><institution>Mayo Clinic, Rochester, Minnesota 55905, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Department of Pathology, </institution><institution>Mayo Clinic, Rochester, Minnesota 55905, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Surgery, </institution><institution>Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Pathology, </institution><institution>Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="GRID">grid.466904.9</institution-id><institution>N. N. Blokhin Russian Cancer Research Center RAMS, Moscow 115478, Russia., </institution></institution-wrap>, </aff>
          <aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="GRID">grid.419890.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0626 690X</institution-id><institution>Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff55"><label>55</label><institution-wrap><institution-id institution-id-type="GRID">grid.412745.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9132 1600</institution-id><institution>Ontario Tumour Bank, London Health Sciences Centre, London, Ontario N6A 5A5, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff56"><label>56</label>St Petersburg Academic University, St Petersburg 199034, Russia., , </aff>
          <aff id="Aff57"><label>57</label><institution-wrap><institution-id institution-id-type="GRID">grid.231844.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0474 0428</institution-id><institution>Department of Pathology, </institution><institution>University Health Network, Toronto, Ontario M5G 2C4, Canada., </institution></institution-wrap>, </aff>
          <aff id="Aff58"><label>58</label><institution-wrap><institution-id institution-id-type="GRID">grid.410445.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2188 0957</institution-id><institution>University of Hawaii, Honolulu, Hawaii 96813, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff59"><label>59</label><institution-wrap><institution-id institution-id-type="GRID">grid.50956.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2152 9905</institution-id><institution>Cedars-Sinai Medical Center, Los Angeles, California 90024, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff60"><label>60</label><institution-wrap><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff61"><label>61</label><institution-wrap><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution>Washington University School of Medicine, St Louis, Missouri 63110, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff62"><label>62</label><institution-wrap><institution-id institution-id-type="GRID">grid.421489.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 4656 9526</institution-id><institution>SRA International, Fairfax, Virgina 22033, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff63"><label>63</label><institution-wrap><institution-id institution-id-type="GRID">grid.280128.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2233 9230</institution-id><institution>Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff64"><label>64</label><institution-wrap><institution-id institution-id-type="GRID">grid.1024.7</institution-id><institution-id institution-id-type="ISNI">0000000089150953</institution-id><institution>Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4059, Australia., </institution></institution-wrap>, </aff>
          <aff id="Aff65"><label>65</label><institution-wrap><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution>Department of Biomedical Statistics and Informatics, </institution><institution>Mayo Clinic, Rochester, Minnesota 55905, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff66"><label>66</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff67"><label>67</label><institution-wrap><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 5165</institution-id><institution>The Cancer Genome Atlas Program Office, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., </institution></institution-wrap>, </aff>
          <aff id="Aff68"><label>68</label>Scimentis, LLC, Atlanta, Georgia 30666, USA., , </aff>
          <aff id="Aff69"><label>69</label>MLF Consulting, Arlington, Maryland 02474, USA., , </aff>
          <aff id="Aff70"><label>70</label><institution-wrap><institution-id institution-id-type="GRID">grid.280128.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2233 9230</institution-id><institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., </institution></institution-wrap>, </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>1</day>
          <month>5</month>
          <year>2013</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <year>2013</year>
        </pub-date>
        <volume>497</volume>
        <issue>7447</issue>
        <issue-id pub-id-type="pmc-issue-id">363944</issue-id>
        <fpage>67</fpage>
        <lpage>73</lpage>
        <history>
          <date date-type="received">
            <day>10</day>
            <month>12</month>
            <year>2012</year>
          </date>
          <date date-type="accepted">
            <day>21</day>
            <month>3</month>
            <year>2013</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>05</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>02</day>
              <month>11</month>
              <year>2013</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-02-08 18:25:11.160">
              <day>08</day>
              <month>02</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-version" specific-use="live">
            <article-id pub-id-type="pmcaiid">3704730</article-id>
            <article-id pub-id-type="doi">10.1038/nature12113</article-id>
            <article-id pub-id-type="manuscript-id">NIHMS458933</article-id>
            <article-version>1</article-version>
            <pub-date>
              <day>02</day>
              <month>05</month>
              <year>2013</year>
            </pub-date>
          </event>
          <event event-type="pmc-version" specific-use="live">
            <article-id pub-id-type="pmcaiid">7449520</article-id>
            <article-id pub-id-type="doi">10.1038/nature12113</article-id>
            <article-version>2</article-version>
            <pub-date>
              <day>01</day>
              <month>05</month>
              <year>2013</year>
            </pub-date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2013</copyright-statement>
          <license license-type="OpenAccess">
            <license-p>This work is licensed under a Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported licence. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41586_2013_Article_BFnature12113.pdf"/>
        <related-article related-article-type="commentary" xml:lang="en" vol="10" page="304"/>
        <related-article related-article-type="correction-forward" xml:lang="en" vol="500" page="242"/>
        <abstract id="Abs1">
          <p id="Par1">We performed an integrated genomic, transcriptomic and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumours and ∼25% of high-grade endometrioid tumours had extensive copy number alterations, few DNA methylation changes, low oestrogen receptor/progesterone receptor levels, and frequent <italic toggle="yes">TP53</italic> mutations. Most endometrioid tumours had few copy number alterations or <italic toggle="yes">TP53</italic> mutations, but frequent mutations in <italic toggle="yes">PTEN</italic>, <italic toggle="yes">CTNNB1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">ARID1A</italic> and <italic toggle="yes">KRAS</italic> and novel mutations in the SWI/SNF chromatin remodelling complex gene <italic toggle="yes">ARID5B</italic>. A subset of endometrioid tumours that we identified had a markedly increased transversion mutation frequency and newly identified hotspot mutations in <italic toggle="yes">POLE</italic>. Our results classified endometrial cancers into four categories: <italic toggle="yes">POLE</italic> ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours.</p>
          <sec>
            <title>Supplementary information</title>
            <p>The online version of this article (doi:10.1038/nature12113) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <abstract id="Abs2" abstract-type="web-summary">
          <p id="Par2">An integrative genomic analysis of several hundred endometrial carcinomas shows that a minority of tumour samples carry copy number alterations or <italic toggle="yes">TP53</italic> mutations and many contain key cancer-related gene mutations, such as those involved in canonical pathways and chromatin remodelling; a reclassification of endometrial tumours into four distinct types is proposed, which may have an effect on patient treatment regimes.</p>
          <sec>
            <title>Supplementary information</title>
            <p>The online version of this article (doi:10.1038/nature12113) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <abstract id="Abs3" abstract-type="LongSummary">
          <title>Reclassification of uterine carcinomas</title>
          <p id="Par3">This paper from The Cancer Genome Atlas Research Network presents an in-depth genome-wide analysis of endometrial (uterine) carcinomas from more than 350 patients. Based on a series of genomic features including newly identified hotspot mutations in the DNA polymerase gene <italic toggle="yes">POLE</italic>, and novel mutations in the ARID5B DNA-binding protein, the authors propose a reclassification of endometrial tumours into four distinct types. This might have clinical relevance for post-surgical adjuvant treatment of women with aggressive tumours.</p>
          <sec>
            <title>Supplementary information</title>
            <p>The online version of this article (doi:10.1038/nature12113) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Cancer genomics</kwd>
          <kwd>Endometrial cancer</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© Springer Nature Limited 2013</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1">
        <title>Main</title>
        <p id="Par4">Endometrial cancer arises from the lining of the uterus. It is the fourth most common malignancy among women in the United States, with an estimated 49,500 new cases and 8,200 deaths in 2013 (ref. <xref ref-type="bibr" rid="CR1">1</xref>). Most patients present with low-grade, early-stage disease. The majority of patients with more aggressive, high-grade tumours who have disease spread beyond the uterus will progress within 1 year (refs <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>). Endometrial cancers have been broadly classified into two groups<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Type I endometrioid tumours are linked to oestrogen excess, obesity, hormone-receptor positivity, and favourable prognosis compared with type II, primarily serous, tumours that are more common in older, non-obese women and have a worse outcome. Early-stage endometrioid cancers are often treated with adjuvant radiotherapy, whereas serous tumours are treated with chemotherapy, similar to advanced-stage cancers of either histological subtype. Therefore, proper subtype classification is crucial for selecting appropriate adjuvant therapy.</p>
        <p id="Par5">Several previous reports suggest that <italic toggle="yes">PTEN</italic> mutations occur early in the neoplastic process of type I tumours and co-exist frequently with other mutations in the phosphatidylinositol-3-OH kinase (PI(3)K)/AKT pathway<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. Other commonly mutated genes in type I tumours include <italic toggle="yes">FGFR2</italic>, <italic toggle="yes">ARID1A</italic>, <italic toggle="yes">CTNNB1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">PIK3R1</italic> and <italic toggle="yes">KRAS</italic><sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. Microsatellite instability (MSI) is found in approximately one-third of type I tumours, but is infrequent in type II tumours<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. <italic toggle="yes">TP53</italic>, <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">PPP2R1A</italic> mutations are frequent in type II tumours<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Most of these studies have been limited to DNA sequencing only with samples of heterogeneous histological subtypes and tumour grades. We present a comprehensive, multiplatform analysis of 373 endometrial carcinomas including low-grade endometrioid, high-grade endometrioid, and serous carcinomas. This integrated analysis provides key molecular insights into tumour classification, which may have a direct effect on treatment recommendations for patients, and provides opportunities for genome-guided clinical trials and drug development.</p>
      </sec>
      <sec id="Sec2">
        <title>Results</title>
        <p id="Par6">Tumour samples and corresponding germline DNA were collected from 373 patients, including 307 endometrioid and 66 serous (53) or mixed histology (13) cases. Local Institutional Review Boards approved all tissue acquisition. The clinical and pathological characteristics of the samples generally reflect a cross-section of individuals with recurrent endometrial cancer<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup> (<xref rid="MOESM88" ref-type="media">Supplementary Table 1.1</xref>). The median follow-up of the cohort was 32 months (range, 1–195 months); 21% of the patients have recurred, and 11% have died. Comprehensive molecular analyses were performed at independent centres using six genomic or proteomic platforms (<xref rid="MOESM88" ref-type="media">Supplementary Table 1.2</xref>). MSI testing performed on all samples using seven repeat loci (<xref rid="MOESM88" ref-type="media">Supplementary Table 1.3</xref>) found MSI in 40% of endometrioid tumours and 2% of serous tumours.</p>
      </sec>
      <sec id="Sec3">
        <title>Somatic copy number alterations</title>
        <p id="Par7">Somatic copy number alterations (SCNAs) were assessed in 363 endometrial carcinomas. Unsupervised hierarchical clustering grouped the tumours into four clusters (<xref rid="Fig1" ref-type="fig">Fig. 1a</xref>). The first three copy-number clusters were composed almost exclusively (97%) of endometrioid tumours without significant differences in tumour grades. Cluster 1 tumours were nearly devoid of broad SCNAs, averaging less than 0.5% genome alteration, with no significant recurrent events. Cluster 1 tumours also had significantly increased non-synonymous mutation rates compared to all others (median 7.2 × 10<sup>−6</sup> versus 1.7 × 10<sup>−6</sup> mutations per megabase (Mb), <italic toggle="yes">P</italic> &lt; 0.001). Copy-number clusters 2 and 3 consisted mainly of endometrioid tumours, distinguished by more frequent 1q amplification in cluster 3 than cluster 2 (100% of cluster 3 tumours versus 33% of cluster 2 tumours) and worse progression-free survival (<italic toggle="yes">P</italic> = 0.003, log-rank versus clusters 1 and 2; <xref rid="Fig1" ref-type="fig">Fig. 1b</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><title>SCNAs in endometrial carcinomas.</title><p><bold>a</bold>, Tumours were hierarchically clustered into four groups based on SCNAs. The heat map shows SCNAs in each tumour (horizontal axis) plotted by chromosomal location (vertical axis). Chr., chromosome. <bold>b</bold>, Kaplan–Meier curves of progression-free survival for each copy-number cluster.</p><p>
<xref rid="MOESM83" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e3254" position="float" orientation="portrait" xlink:href="41586_2013_Article_BFnature12113_Fig1_HTML.jpg"/></fig></p>
        <p id="Par8">Most of the serous (50 out of 53; 94%) and mixed histology (8 out of 13; 62%) tumours clustered with 36 (12%) of the 289 endometrioid tumours, including 24% of grade 3 and 5% of grade 1 or 2, into copy-number cluster 4; a single group characterized by a very high degree of SCNAs (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 2.1</xref>; focal SCNAs with false discovery rate (FDR) &lt; 0.15, and <xref rid="MOESM88" ref-type="media">Supplementary Data 2.1</xref>). Cluster 4 tumours were characterized by significantly recurrent previously reported focal amplifications of the oncogenes <italic toggle="yes">MYC</italic> (8q24.12), <italic toggle="yes">ERBB2</italic> (17q12) and <italic toggle="yes">CCNE1</italic> (19q12)<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, and by SCNAs previously unreported in endometrial cancers including those containing <italic toggle="yes">FGFR3</italic> (4p16.3) and <italic toggle="yes">SOX17</italic> (8q11.23). Cluster 4 tumours also had frequent <italic toggle="yes">TP53</italic> mutations (90%), little MSI (6%), and fewer <italic toggle="yes">PTEN</italic> mutations (11%) than other endometrioid tumours (84%). Overall, these findings suggest that a subset of endometrial tumours contain distinct patterns of SCNAs and mutations that do not correlate with traditional tumour histology or grade.</p>
        <p id="Par9">As expected, tumours in the ‘serous-like’ cluster (cluster 4) had significantly worse progression-free survival than tumours in the endometrioid cluster groups (<italic toggle="yes">P</italic> = 0.003, log-rank, <xref rid="Fig1" ref-type="fig">Fig. 1b</xref>). Potential therapeutically relevant SCNAs included the cluster 2 15q26.2 focal amplification, which contained <italic toggle="yes">IGF1R</italic>; and cluster 4 amplifications of <italic toggle="yes">ERBB2</italic>, <italic toggle="yes">FGFR1</italic> and <italic toggle="yes">FGFR3</italic>, and <italic toggle="yes">LRP1B</italic> deletion, which was recently associated with resistance to liposomal doxorubicin in serous ovarian cancer<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p>
      </sec>
      <sec id="Sec4">
        <title>Exome sequence analysis</title>
        <p id="Par10">We sequenced the exomes of 248 tumour/normal pairs. On the basis of a combination of somatic nucleotide substitutions, MSI and SCNAs, the endometrial tumours were classified into four groups (<xref rid="Fig2" ref-type="fig">Fig. 2a, b</xref>): (1) an ultramutated group with unusually high mutation rates (232 × 10<sup>−6</sup> mutations per Mb) and a unique nucleotide change spectrum; (2) a hypermutated group (18 × 10<sup>−6</sup> mutations per Mb) of MSI tumours, most with <italic toggle="yes">MLH1</italic> promoter methylation; (3) a group with lower mutation frequency (2.9 × 10<sup>−6</sup> mutations per Mb) and most of the microsatellite stable (MSS) endometrioid cancers; and (4) a group that consists primarily of serous-like cancers with extensive SCNA (copy-number cluster 4) and a low mutation rate (2.3 × 10<sup>−6</sup> mutations per Mb). The ultramutated group consisted of 17 (7%) tumours exemplified by an increased C→A transversion frequency, all with mutations in the exonuclease domain of <italic toggle="yes">POLE</italic>, and an improved progression-free survival (<xref rid="Fig2" ref-type="fig">Fig. 2a, c</xref>). <italic toggle="yes">POLE</italic> is a catalytic subunit of DNA polymerase epsilon involved in nuclear DNA replication and repair. We identified hotspot mutations in <italic toggle="yes">POLE</italic> at Pro286Arg and Val411Leu present in 13 (76%) of the 17 ultramutated samples. Significantly mutated genes (SMGs) identified at low FDRs (<italic toggle="yes">Q</italic>) in this subset included <italic toggle="yes">PTEN</italic> (94%, <italic toggle="yes">Q</italic> = 0), <italic toggle="yes">PIK3R1</italic> (65%, <italic toggle="yes">Q</italic> = 8.3 × 10<sup>−7</sup>), <italic toggle="yes">PIK3CA</italic> (71%, <italic toggle="yes">Q</italic> = 9.1 × 10<sup>−5</sup>), <italic toggle="yes">FBXW7</italic> (82%, <italic toggle="yes">Q</italic> = 1.4 × 10<sup>−4</sup>), <italic toggle="yes">KRAS</italic> (53%, <italic toggle="yes">Q</italic> = 9.2 × 10<sup>−4</sup>) and <italic toggle="yes">POLE</italic> (100%, <italic toggle="yes">Q</italic> = 4.2 × 10<sup>−3</sup>). Mutation rates in <italic toggle="yes">POLE</italic> mutant endometrial and previously reported ultramutated colorectal tumours exceeded those found in any other lineage including lung cancer and melanoma<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Germline susceptibility variants have been reported in <italic toggle="yes">POLE</italic> (Leu424Val) and <italic toggle="yes">POLD1</italic> (Ser478Asn), but were not found in our endometrial normal exome-seq reads<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.<fig id="Fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><title>Mutation spectra across endometrial carcinomas.</title><p><bold>a</bold>, Mutation frequencies (vertical axis, top panel) plotted for each tumour (horizontal axis). Nucleotide substitutions are shown in the middle panel, with a high frequency of C-to-A transversions in the samples with <italic toggle="yes">POLE</italic> exonuclease mutations. CN, copy number. <bold>b</bold>, Tumours were stratified into the four groups by (1) nucleotide substitution frequencies and patterns, (2) MSI status, and (3) copy-number cluster. SNV, single nucleotide variant. <bold>c</bold>, <italic toggle="yes">POLE</italic>-mutant tumours have significantly better progression-free survival, whereas copy-number high tumours have the poorest outcome. <bold>d</bold>, Recurrently mutated genes are different between the four subgroups. Shown are the mutation frequencies of all genes that were significantly mutated in at least one of the four subgroups (MUSiC, asterisk denotes FDR &lt; 0.05).</p><p>
<xref rid="MOESM84" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e3466" position="float" orientation="portrait" xlink:href="41586_2013_Article_BFnature12113_Fig2_HTML.jpg"/></fig></p>
        <p id="Par11">The MSI endometrioid tumours had a mutation frequency approximately tenfold greater than MSS endometrioid tumours, few SCNAs, frameshift deletions in <italic toggle="yes">RPL22</italic>, frequent non-synonymous <italic toggle="yes">KRAS</italic> mutations, and few mutations in <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">CTNNB1</italic>, <italic toggle="yes">PPP2R1A</italic> and <italic toggle="yes">TP53</italic>. The MSS, copy-number low, endometrioid tumours had an unusually high frequency of <italic toggle="yes">CTNNB1</italic> mutations (52%); the only gene with a higher mutation frequency than the MSI samples. The copy-number high group contained all of the remaining serous cases and one-quarter of the grade 3 endometrioid cases. Most of these tumours had <italic toggle="yes">TP53</italic> mutations and a high frequency of <italic toggle="yes">FBXW7</italic> (22%, <italic toggle="yes">Q</italic> = 0) and <italic toggle="yes">PPP2R1A</italic> (22%, <italic toggle="yes">Q</italic> = 1.7 × 10<sup>−16</sup>) mutations, previously reported as common in uterine serous but not endometrioid carcinomas. Thus, a subset of high-grade endometrioid tumours had similar SCNAs and mutation spectra as uterine serous carcinomas, suggesting that these patients might benefit from treatment approaches that parallel those for serous tumours.</p>
        <p id="Par12">There were 48 genes with differential mutation frequencies across the four groups (<xref rid="Fig2" ref-type="fig">Fig. 2d</xref> and <xref rid="MOESM88" ref-type="media">Supplementary Data 3.1</xref>). <italic toggle="yes">ARID5B</italic>, a member of the same AT-rich interaction domain (ARID) family as <italic toggle="yes">ARID1A</italic>, was more frequently mutated in MSI (23.1%) than in either MSS endometrioid (5.6%) or high SCNA serous tumours (0%), a novel finding for endometrial cancer. Frameshifting <italic toggle="yes">RPL22</italic> indels near a homopolymer at Lys 15 were almost exclusively found in the MSI group (36.9%). The <italic toggle="yes">TP53</italic> mutation frequency (&gt;90%) in serous tumours differentiated them from the endometrioid subtypes (11.4%). However, many (10 out of 20; 50%) endometrioid tumours with a non-silent <italic toggle="yes">TP53</italic> mutation also had non-silent mutations in <italic toggle="yes">PTEN</italic>, compared to only 1 out of 39 (2.6%) serous tumours with non-silent <italic toggle="yes">TP53</italic> mutations. Although <italic toggle="yes">TP53</italic> mutations are not restricted to serous tumours, the co-existing <italic toggle="yes">PTEN</italic> mutations in the endometrioid cases suggest a distinct tumorigenic mechanism.</p>
        <p id="Par13">Comparisons of 66 SMGs between traditional histological subtypes are provided (<xref rid="MOESM88" ref-type="media">Supplementary Methods 3</xref>), and SMGs across other subcohorts can be found in <xref rid="MOESM88" ref-type="media">Supplementary Data 3.2</xref>. The spectrum of <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">PTEN</italic> mutations in endometrial cancer also differed from other solid tumours (<xref rid="MOESM88" ref-type="media">Supplementary Methods 3</xref>). Integrated analysis may be useful for identifying histologically misclassified cases. For example, a single serous case was identified without a <italic toggle="yes">TP53</italic> mutation or extensive SCNAs and with a <italic toggle="yes">KRAS</italic> mutation and high mutation rate. After re-review of the histological section, the case was deemed consistent with a grade 3 endometrioid tumour, demonstrating how molecular analysis could reclassify tumour histology and potentially affect treatment decisions.</p>
      </sec>
      <sec id="Sec5">
        <title>Multiplatform subtype classifications</title>
        <p id="Par14">All of the endometrial tumours were examined for messenger RNA expression (<italic toggle="yes">n</italic> = 333), protein expression (<italic toggle="yes">n</italic> = 293), microRNA expression (<italic toggle="yes">n</italic> = 367), and DNA methylation (<italic toggle="yes">n</italic> = 373) (<xref rid="MOESM88" ref-type="media">Supplementary Methods 4–7</xref>). Unsupervised <italic toggle="yes">k</italic>-means clustering of mRNA expression from RNA sequencing identified three robust clusters termed ‘mitotic’, ‘hormonal’ and ‘immunoreactive’ (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 4.1</xref>) that were significantly correlated with the four integrated clusters; <italic toggle="yes">POLE</italic>, MSI, copy-number low and copy-number high (<italic toggle="yes">P</italic> &lt; 0.0001). Supervised analysis identified signature genes of the <italic toggle="yes">POLE</italic> cluster (<italic toggle="yes">n</italic> = 17) mostly involved in cellular metabolism (<xref rid="Fig3" ref-type="fig">Fig. 3a</xref>). Among the few signature genes in the MSI cluster was decreased <italic toggle="yes">MLH1</italic> mRNA expression, probably due to its promoter methylation. Increased progesterone receptor (<italic toggle="yes">PGR</italic>) expression was noted in the copy-number low cluster, suggesting responsiveness to hormonal therapy. The copy-number high cluster, which included most of the serous and serous-like endometrioid tumours, exhibited the greatest transcriptional activity exemplified by increased cell cycle deregulation (for example, <italic toggle="yes">CCNE1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">MYC</italic> and <italic toggle="yes">CDKN2A</italic>) and <italic toggle="yes">TP53</italic> mutation (<xref rid="MOESM88" ref-type="media">Supplementary Figs 4.2 and 4.3</xref>). This is consistent with reports that increased CDKN2A can distinguish serous from endometrioid carcinomas<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Approximately 85% of cases in the copy-number high cluster shared membership with the ‘mitotic’ mRNA subtype.<fig id="Fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><title>Gene expression across integrated subtypes in endometrial carcinomas.</title><p><bold>a</bold>, Supervised analysis of ∼1,500 genes significantly associated with integrated subtypes. <bold>b</bold>, Heat map of protein expression clusters, supervised by integrated subtypes. Samples are in columns; genes or proteins are in rows.</p><p>
<xref rid="MOESM85" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e3662" position="float" orientation="portrait" xlink:href="41586_2013_Article_BFnature12113_Fig3_HTML.jpg"/></fig></p>
        <p id="Par15">Supervised clustering of the reverse phase protein array (RPPA) expression data was consistent with loss of function for many of the mutated genes (<xref rid="Fig3" ref-type="fig">Fig. 3b</xref>). <italic toggle="yes">TP53</italic> was frequently mutated in the copy-number high group (<italic toggle="yes">P</italic> = 2.5 × 10<sup>−27</sup>) and its protein expression was also increased, suggesting that these mutations are associated with increased expression. By contrast, <italic toggle="yes">PTEN</italic> (<italic toggle="yes">P</italic> = 2.8 × 10<sup>−19</sup>) and <italic toggle="yes">ARID1A</italic> (<italic toggle="yes">P</italic> = 1.2 × 10<sup>−6</sup>) had high mutation rates in the remaining groups, but their expression was decreased, suggesting inactivating mutations in both genes. The copy-number high group also had decreased levels of phospho-AKT, consistent with downregulation of the AKT pathway. The copy-number low group had raised RAD50 expression, which is associated with DNA repair, explaining some of the differences between the copy-number high and low groups. The <italic toggle="yes">POLE</italic> group had high expression of ASNS and CCNB1, whereas the MSI tumours had both high phospho-AKT and low PTEN expression.</p>
        <p id="Par16">Unsupervised clustering of DNA methylation data generated from Illumina Infinium DNA methylation arrays revealed four unique subtypes (MC1–4) that support the four integrative clusters. A heavily methylated subtype (MC1) reminiscent of the CpG island methylator phenotype (CIMP) described in colon cancers and glioblastomas<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup> was associated with the MSI subtype and attributable to promoter hypermethylation of <italic toggle="yes">MLH1</italic>. A serous-like cluster (MC3) with minimal DNA methylation changes was composed primarily of serous tumours and some endometrioid tumours (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 7.1</xref>) and contained most of the copy-number high tumours.</p>
        <p id="Par17">Integrative clustering using the iCluster framework returned two major clusters split primarily on serous and endometrioid histology highlighting <italic toggle="yes">TP53</italic> mutations, lack of <italic toggle="yes">PTEN</italic> mutation and encompassing almost exclusively copy-number high tumours<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 8.1</xref>). We developed a new clustering algorithm, called SuperCluster, to derive overall subtypes based on sample cluster memberships across all data types (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 9.1</xref>). SuperCluster identified four clusters that generally confirmed the contributions of individual platforms to the overall integrated clusters. No major batch effects were identified for any platform (<xref rid="MOESM88" ref-type="media">Supplementary Methods 10</xref>).</p>
      </sec>
      <sec id="Sec6">
        <title>Structural aberrations</title>
        <p id="Par18">To identify somatic chromosomal aberrations, we performed low-pass, paired-end, whole-genome sequencing on 106 tumours with matched normals. We found recurrent translocations involving genes in several pathways including WNT, EGFR–RAS–MAPK, PI(3)K, protein kinase A, retinoblastoma and apoptosis. The most frequent translocations (5 out of 106) involved a member of the BCL family (<italic toggle="yes">BCL2</italic>, <italic toggle="yes">BCL7A</italic>, <italic toggle="yes">BCL9</italic> and <italic toggle="yes">BCL2L11</italic>). Four of these were confirmed by identification of the translocation junction point and two were also confirmed by high-throughput RNA sequencing (RNA-Seq). In all cases the translocations result in in-frame fusions and are predicted to result in activation or increased expression of the BCL family members (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 3.2</xref>). Translocations involving members of the BCL family leading to reduced apoptosis have been described in other tumour types<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> and our results suggest that similar mechanisms may be operative here.</p>
      </sec>
      <sec id="Sec7">
        <title>Pathway alterations</title>
        <p id="Par19">Multiple platform data were integrated to identify recurrently altered pathways in the four endometrial cancer integrated subgroups. Because of the high background mutation rate and small sample size, we excluded the <italic toggle="yes">POLE</italic> subgroup from this analysis. Considering all recurrently mutated, homozygously deleted, and amplified genes, we used MEMo<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> to identify gene networks with mutually exclusive alteration patterns in each subgroup. The most significant module was found in the copy-number low group and contained <italic toggle="yes">CTNNB1</italic>, <italic toggle="yes">KRAS</italic> and <italic toggle="yes">SOX17</italic> (<xref rid="Fig4" ref-type="fig">Fig. 4a</xref>). The very strong mutual exclusivity between mutations in these three genes suggests that alternative mechanisms activate WNT signalling in endometrioid endometrial cancer. Activating <italic toggle="yes">KRAS</italic> mutations have been shown to increase the stability of β-catenin via glycogen synthase kinase 3β (GSK-3β), leading to an alternative mechanism of β-catenin activation other than adenomatous polyposis coli degradation<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. <italic toggle="yes">SOX17</italic>, which mediates proteasomal degradation of β-catenin<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>, is mutated exclusively in the copy-number low group (8%) at recurrent positions (Ala96Gly and Ser403Ile) not previously described. Other genes with mutually exclusive alteration patterns in this module were <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">FGFR2</italic> and <italic toggle="yes">ERBB2</italic> (ref. <xref ref-type="bibr" rid="CR29">29</xref>). <italic toggle="yes">ERBB2</italic> was focally amplified with protein overexpression in 25% of the serous or serous-like tumours, suggesting a potential role for human epidermal growth factor receptor 2 (HER2)-targeted inhibitors. A small clinical trial of trastuzumab found no activity in endometrial carcinoma, but accrued few HER2 fluorescence <italic toggle="yes">in situ</italic> hybridization (FISH)-amplified serous carcinomas<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.<fig id="Fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><title>Pathway alterations in endometrial carcinomas.</title><p><bold>a</bold>, The RTK/RAS/β-catenin pathway is altered through several mechanisms that exhibit mutually exclusive patterns. Alteration frequencies are expressed as a percentage of all cases. The right panel shows patterns of occurrence. <bold>b</bold>, The PI(3)K pathway has mutually exclusive <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">PIK3R1</italic> alterations that frequently co-occur with <italic toggle="yes">PTEN</italic> alterations in the MSI and copy-number low subgroups. <bold>c</bold>, Heat map display of top 1,000 varying pathway features within PARADIGM consensus clusters. Samples were arranged in order of their consensus cluster membership. The genomic subtype for each sample is displayed below the consensus clusters.</p><p>
<xref rid="MOESM86" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e3862" position="float" orientation="portrait" xlink:href="41586_2013_Article_BFnature12113_Fig4_HTML.jpg"/></fig></p>
        <p id="Par20"><italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">PIK3R1</italic> mutations were frequent and showed a strong tendency for mutual exclusivity in all subgroups, but unlike other tumour types, they co-occurred with <italic toggle="yes">PTEN</italic> mutations in the MSI and copy-number low subgroups as previously reported<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup> (<xref rid="Fig4" ref-type="fig">Fig. 4b</xref>). The copy-number high subgroup showed mutual exclusivity between alterations of all three genes. Overall, 93% of endometrioid tumours had mutations that suggested potential for targeted therapy with PI(3)K/AKT pathway inhibitors.</p>
        <p id="Par21">Consensus clustering of copy number, mRNA expression and pathway interaction data for 324 samples yielded five PARADIGM clusters with distinct pathway activation patterns<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (<xref rid="Fig4" ref-type="fig">Fig. 4c</xref> and <xref rid="MOESM88" ref-type="media">Supplementary Methods 11</xref>). PARADIGM cluster 1 had the lowest level of MYC pathway activation and highest level of WNT pathway activation, consistent with its composition of copy-number low cases having frequent <italic toggle="yes">CTNNB1</italic> mutations. PARADIGM cluster 3 was composed predominantly of the copy-number high cases, with relatively high MYC/MAX signalling but low oestrogen receptor/FOXA1 signalling and p53 activity. Only <italic toggle="yes">TP53</italic> truncation and not missense mutations were implicated as loss-of-function mutations, suggesting different classes of p53 mutations may have distinct signalling consequences. PARADIGM cluster 5 was enriched for hormone receptor expression.</p>
      </sec>
      <sec id="Sec8">
        <title>Comparison to ovarian and breast cancers</title>
        <p id="Par22">The clinical and pathologic features of uterine serous carcinoma and high-grade serous ovarian carcinoma (HGSOC) are quite similar. HGSOC shares many similar molecular features with basal-like breast carcinoma<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Focal SCNA patterns were similar between these three tumour subtypes and unsupervised clustering identified relatedness (<xref rid="Fig5" ref-type="fig">Fig. 5a</xref> and <xref rid="MOESM88" ref-type="media">Supplementary Fig. 12.1</xref>). Supervised analysis of transcriptome data sets showed high correlation between tumour subtypes (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 12.2</xref>). The MC3 DNA methylation subtype with minimal DNA methylation changes was also similar to basal-like breast and HGSOCs (<xref rid="MOESM88" ref-type="media">Supplementary Fig. 12.3</xref>). A high frequency of <italic toggle="yes">TP53</italic> mutations is shared across these tumour subtypes (uterine serous, 91%; HGSOC, 96%; basal-like breast, 84%)<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>, as is the very low frequency of <italic toggle="yes">PTEN</italic> mutations (uterine serous, 2%; HGSOC, 1%; basal-like breast, 1%). Differences included a higher frequency of <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">PPP2R1A</italic> and <italic toggle="yes">PIK3CA</italic> mutations in uterine serous compared to basal-like breast and HGSOCs (<xref rid="Fig5" ref-type="fig">Fig. 5b</xref>). We showed that uterine serous carcinomas share many molecular features with both HGSOCs and basal-like breast carcinomas, despite more frequent mutations, suggesting new opportunities for overlapping treatment paradigms.<fig id="Fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><title>Genomic relationships between endometrial serous-like, ovarian serous, and basal-like breast carcinomas.</title><p><bold>a</bold>, SCNAs for each tumour type. <bold>b</bold>, Frequency of genomic alterations present in at least 10% of one tumour type.</p><p>
<xref rid="MOESM87" ref-type="media">PowerPoint slide</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d30e3969" position="float" orientation="portrait" xlink:href="41586_2013_Article_BFnature12113_Fig5_HTML.jpg"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Discussion</title>
        <p id="Par23">This integrated genomic and proteomic analysis of 373 endometrial cancers provides insights into disease biology and diagnostic classification that could have immediate therapeutic application. Our analysis identified four new groups of tumours based on integrated genomic data, including a novel <italic toggle="yes">POLE</italic> subtype in ∼10% of endometrioid tumours. Ultrahigh somatic mutation frequency, MSS, and common, newly identified hotspot mutations in the exonuclease domain of <italic toggle="yes">POLE</italic> characterize this subtype. SCNAs add a layer of resolution, revealing that most endometrioid tumours have few SCNAs, most serous and serous-like tumours exhibit extensive SCNAs, and the extent of SCNA roughly correlates with progression-free survival.</p>
        <p id="Par24">Endometrial cancer has more frequent mutations in the PI(3)K/AKT pathway than any other tumour type studied by The Cancer Genome Atlas (TCGA) so far. Endometrioid endometrial carcinomas share many characteristics with colorectal carcinoma including a high frequency of MSI (40% and 11%, respectively), <italic toggle="yes">POLE</italic> mutations (7% and 3%, respectively) leading to ultrahigh mutation rates, and frequent activation of WNT/CTNNB1 signalling; yet endometrial carcinomas have novel exclusivity of <italic toggle="yes">KRAS</italic> and <italic toggle="yes">CTNNB1</italic> mutations and a distinct mechanism of pathway activation. Uterine serous carcinomas share many similar characteristics with basal-like breast and HGSOCs; three tumour types with high-frequency non-silent <italic toggle="yes">TP53</italic> mutations and extensive SCNA. However, the high frequency of <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">PPP2R1A</italic> and <italic toggle="yes">ARID1A</italic> mutations in uterine serous carcinomas are not found in basal-like breast and HGSOCs. The frequency of mutations in <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">FBXW7</italic> and <italic toggle="yes">PPP2R1A</italic> was ∼30% higher than in a recently reported study of 76 uterine serous carcinomas<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, but similar to another study<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Uterine serous carcinomas have <italic toggle="yes">ERBB2</italic> amplification in 27% of tumours and <italic toggle="yes">PIK3CA</italic> mutations in 42%, which provide translational opportunities for targeted therapeutics.</p>
        <p id="Par25">Early stage type I endometrioid tumours are often treated with adjuvant radiotherapy, whereas similarly staged type II serous tumours are treated with chemotherapy. High-grade serous and endometrioid endometrial carcinomas are difficult to subtype correctly, and intra-observer concordance among speciality pathologists is low<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Our molecular characterization data demonstrate that ∼25% of tumours classified as high-grade endometrioid by pathologists have a molecular phenotype similar to uterine serous carcinomas, including frequent <italic toggle="yes">TP53</italic> mutations and extensive SCNA. The compelling similarities between this subset of endometrioid tumours and uterine serous carcinomas suggest that genomic-based classification may lead to improved management of these patients. Clinicians should carefully consider treating copy-number-altered endometrioid patients with chemotherapy rather than adjuvant radiotherapy and formally test such hypotheses in prospective clinical trials. Furthermore, the marked molecular differences between endometrioid and serous-like tumours suggest that these tumours warrant separate clinical trials to develop the independent treatment paradigms that have improved outcomes in other tumour types, such as breast cancer.</p>
      </sec>
      <sec id="Sec10">
        <title>Methods Summary</title>
        <p id="Par26">Biospecimens were obtained from 373 patients after Institutional Review Board-approved consents. DNA and RNA were co-isolated using a modified AllPrep kit (Qiagen). We used Affymetrix SNP 6.0 microarrays to detect SCNAs in 363 samples and GISTIC analysis to identify recurrent events<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. The exomes of 248 tumours were sequenced to a read-depth of at least ×20. We performed low-pass whole-genome sequencing on 107 tumours to a mean depth of ×6. Consensus clustering was used to analyse mRNA, miRNA, RPPA and methylation data with methods previously described<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. Integrated cross-platform analyses were performed using MEMo, iCluster and PARADIGM<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>.</p>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary information</title>
        <sec id="Sec11">
          <p>
<supplementary-material content-type="local-data" id="MOESM88" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41586_2013_BFnature12113_MOESM88_ESM.pdf" position="float" orientation="portrait"><caption><title>Supplementary Information</title><p>This file contains Supplementary Methods 1-12, which includes Supplementary Figures and Tables and additional references (see pages 1 and 2 for details). (PDF 14394 kb)</p></caption></media></supplementary-material>
</p>
          <p>
<supplementary-material content-type="local-data" id="MOESM89" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41586_2013_BFnature12113_MOESM89_ESM.zip" position="float" orientation="portrait"><caption><title>Supplementary Data</title><p>This zipped file contains Supplementary Data files 1.1, 2.1, 3.1, 3.2 and 5.1 (see Supplementary Information document for details). (ZIP 698 kb)</p></caption></media></supplementary-material>
</p>
        </sec>
      </sec>
    </body>
    <back>
      <app-group>
        <app id="App1">
          <sec id="Sec12">
            <title>PowerPoint slides</title>
            <p id="Par30">
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2013_BFnature12113_MOESM83_ESM.ppt" id="MOESM83" orientation="portrait"><caption><p>PowerPoint slide for Fig. 1</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2013_BFnature12113_MOESM84_ESM.ppt" id="MOESM84" orientation="portrait"><caption><p>PowerPoint slide for Fig. 2</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2013_BFnature12113_MOESM85_ESM.ppt" id="MOESM85" orientation="portrait"><caption><p>PowerPoint slide for Fig. 3</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2013_BFnature12113_MOESM86_ESM.ppt" id="MOESM86" orientation="portrait"><caption><p>PowerPoint slide for Fig. 4</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="41586_2013_BFnature12113_MOESM87_ESM.ppt" id="MOESM87" orientation="portrait"><caption><p>PowerPoint slide for Fig. 5</p></caption></media>
</p>
          </sec>
        </app>
      </app-group>
      <fn-group>
        <fn>
          <p>(Participants are arranged by area of contribution and then by institution.)</p>
        </fn>
        <fn>
          <p>The primary and processed data used to generate the analyses presented here are deposited at the Data Coordinating Center (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp">https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp</ext-link>); all of the primary sequence files are deposited in CGHub (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link>). Sample lists, data matrices and supporting data can be found at: (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/ucec_2013/">https://tcga-data.nci.nih.gov/docs/publications/ucec_2013/</ext-link>). The data can be explored via the cBio Cancer Genomics Portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>). Reprints and permissions information is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/reprints">www.nature.com/reprints</ext-link>. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to D.A.L. (levine2@mskcc.org).</p>
        </fn>
        <fn>
          <p>
            <bold>Change history</bold>
          </p>
          <p>6/12/2013</p>
          <p>Nature 497, 67–73 (2013); doi:10.1038/nature12113 In the ‘Results’ section of this Article, the range in the sentence “The median follow-up of the cohort was 32 months (range, 1–19 months); 21% of the patients have recurred, and 11% have died.” should have been 1–195 months. This error has been corrected in the HTML and PDF versions of the paper.</p>
        </fn>
      </fn-group>
      <ack>
        <title>Acknowledgements</title>
        <p>We wish to thank all patients and families who contributed to this study. We thank M. Sheth and L. Lund for administrative coordination of TCGA activities, G. Monemvasitis for editing the manuscript, and C. Gunter for critical reading of the manuscript. This work was supported by the following grants from the US National Institutes of Health: 5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04, U54HG003067-11, U54HG003079-10 and U54HG003273-10.</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Author Contributions</title>
        <p>The TCGA Research Network contributed collectively to this study. Biospecimens were provided by the tissue source sites and processed by the biospecimen core resource. Data generation and analyses were performed by the genome sequencing centres, cancer genome characterization centres and genome data analysis centres. All data were released through the data coordinating centre. The National Cancer Institute and National Human Genome Research Institute project teams coordinated project activities. We also acknowledge the following TCGA investigators who made substantial contributions to the project: N.S. (manuscript coordinator); J. Gao (data coordinator); C.K. and L. Ding (DNA sequence analysis); W.Z. and Y.L. (mRNA sequence analysis); H.S. and P.W.L. (DNA methylation analysis); A.D.C. and I.P. (copy number analysis); S.L. and A. Hadjipanayis (translocations); N.S., N.W. G.C., C.C.B. and C.Y. (pathway analysis); Andy C. and A.G.R. (miRNA sequence analysis); R. Broaddus, P.J.G., G.B.M. and R.A.S. (pathology and clinical expertise); G.B.M., H.L. and R.A. (reverse phase protein arrays); P.J.G. and R.B. (disease experts); G.B.M. and R.K. (manuscript editing); D.A.L. and E.R.M. (project chairs).</p>
      </notes>
      <notes notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par27">The author declares no competing financial interests.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Siegel</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Naishadham</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2013</article-title>
            <source>CA Cancer J. Clin.</source>
            <year>2013</year>
            <volume>63</volume>
            <fpage>11</fpage>
            <lpage>30</lpage>
            <pub-id pub-id-type="doi">10.3322/caac.21166</pub-id>
            <pub-id pub-id-type="pmid">23335087</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study</article-title>
            <source>J. Clin. Oncol.</source>
            <year>2004</year>
            <volume>22</volume>
            <fpage>2159</fpage>
            <lpage>2166</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2004.07.184</pub-id>
            <pub-id pub-id-type="pmid">15169803</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sutton</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study</article-title>
            <source>Gynecol. Oncol.</source>
            <year>2005</year>
            <volume>97</volume>
            <fpage>755</fpage>
            <lpage>763</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ygyno.2005.03.011</pub-id>
            <pub-id pub-id-type="pmid">15913742</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lax</surname>
                <given-names>SF</given-names>
              </name>
              <name name-style="western">
                <surname>Kurman</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses</article-title>
            <source>Verh. Dtsch. Ges. Pathol.</source>
            <year>1997</year>
            <volume>81</volume>
            <fpage>228</fpage>
            <lpage>232</lpage>
            <pub-id pub-id-type="pmid">9474874</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheung</surname>
                <given-names>LW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>High frequency of <italic toggle="yes">PIK3R1</italic> and <italic toggle="yes">PIK3R2</italic> mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability</article-title>
            <source>Cancer Discov.</source>
            <year>2011</year>
            <volume>1</volume>
            <fpage>170</fpage>
            <lpage>185</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0039</pub-id>
            <pub-id pub-id-type="pmid">21984976</pub-id>
            <pub-id pub-id-type="pmcid">PMC3187555</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title><italic toggle="yes">PTEN</italic> mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma</article-title>
            <source>Cancer Res.</source>
            <year>1998</year>
            <volume>58</volume>
            <fpage>3254</fpage>
            <lpage>3258</lpage>
            <pub-id pub-id-type="pmid">9699651</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McConechy</surname>
                <given-names>MK</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Use of mutation profiles to refine the classification of endometrial carcinomas</article-title>
            <source>J. Pathol.</source>
            <year>2012</year>
            <volume>228</volume>
            <fpage>20</fpage>
            <lpage>30</lpage>
            <pub-id pub-id-type="pmid">22653804</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4056</pub-id>
            <pub-id pub-id-type="pmcid">PMC3939694</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Byron</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title><italic toggle="yes">FGFR2</italic> point mutations in 466 endometrioid endometrial tumors: relationship with MSI, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">CTNNB1</italic> mutations and clinicopathological features</article-title>
            <source>PLoS ONE</source>
            <year>2012</year>
            <volume>7</volume>
            <fpage>e30801</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pone.0030801</pub-id>
            <pub-id pub-id-type="pmid">22383975</pub-id>
            <pub-id pub-id-type="pmcid">PMC3285611</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Urick</surname>
                <given-names>ME</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title><italic toggle="yes">PIK3R1</italic> (p85α) is somatically mutated at high frequency in primary endometrial cancer</article-title>
            <source>Cancer Res.</source>
            <year>2011</year>
            <volume>71</volume>
            <fpage>4061</fpage>
            <lpage>4067</lpage>
            <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0549</pub-id>
            <pub-id pub-id-type="pmid">21478295</pub-id>
            <pub-id pub-id-type="pmcid">PMC3117071</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zighelboim</surname>
                <given-names>I</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Microsatellite instability and epigenetic inactivation of <italic toggle="yes">MLH1</italic> and outcome of patients with endometrial carcinomas of the endometrioid type</article-title>
            <source>J. Clin. Oncol.</source>
            <year>2007</year>
            <volume>25</volume>
            <fpage>2042</fpage>
            <lpage>2048</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2006.08.2107</pub-id>
            <pub-id pub-id-type="pmid">17513808</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kuhn</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses</article-title>
            <source>J. Natl. Cancer Inst.</source>
            <year>2012</year>
            <volume>104</volume>
            <fpage>1503</fpage>
            <lpage>1513</lpage>
            <pub-id pub-id-type="doi">10.1093/jnci/djs345</pub-id>
            <pub-id pub-id-type="pmid">22923510</pub-id>
            <pub-id pub-id-type="pmcid">PMC3692380</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Le Gallo</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes</article-title>
            <source>Nature Genet.</source>
            <year>2012</year>
            <volume>44</volume>
            <fpage>1310</fpage>
            <lpage>1315</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.2455</pub-id>
            <pub-id pub-id-type="pmid">23104009</pub-id>
            <pub-id pub-id-type="pmcid">PMC3515204</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Salvesen</surname>
                <given-names>HB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2009</year>
            <volume>106</volume>
            <fpage>4834</fpage>
            <lpage>4839</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.0806514106</pub-id>
            <pub-id pub-id-type="pmid">19261849</pub-id>
            <pub-id pub-id-type="pmcid">PMC2660768</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cowin</surname>
                <given-names>PA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin</article-title>
            <source>Cancer Res.</source>
            <year>2012</year>
            <volume>72</volume>
            <fpage>4060</fpage>
            <lpage>4073</lpage>
            <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0203</pub-id>
            <pub-id pub-id-type="pmid">22896685</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15</label>
          <mixed-citation publication-type="other">The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. <italic toggle="yes">Nature</italic><bold>487</bold>, 330–337 (2012)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11252</pub-id><pub-id pub-id-type="pmcid">PMC3401966</pub-id><pub-id pub-id-type="pmid">22810696</pub-id></mixed-citation>
        </ref>
        <ref id="CR16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Govindan</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic landscape of non-small cell lung cancer in smokers and never-smokers</article-title>
            <source>Cell</source>
            <year>2012</year>
            <volume>150</volume>
            <fpage>1121</fpage>
            <lpage>1134</lpage>
            <pub-id pub-id-type="doi">10.1016/j.cell.2012.08.024</pub-id>
            <pub-id pub-id-type="pmid">22980976</pub-id>
            <pub-id pub-id-type="pmcid">PMC3656590</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pleasance</surname>
                <given-names>ED</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A comprehensive catalogue of somatic mutations from a human cancer genome</article-title>
            <source>Nature</source>
            <year>2010</year>
            <volume>463</volume>
            <fpage>191</fpage>
            <lpage>196</lpage>
            <pub-id pub-id-type="doi">10.1038/nature08658</pub-id>
            <pub-id pub-id-type="pmid">20016485</pub-id>
            <pub-id pub-id-type="pmcid">PMC3145108</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Palles</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas</article-title>
            <source>Nature Genet.</source>
            <year>2013</year>
            <volume>45</volume>
            <fpage>136</fpage>
            <lpage>144</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.2503</pub-id>
            <pub-id pub-id-type="pmid">23263490</pub-id>
            <pub-id pub-id-type="pmcid">PMC3785128</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bartosch</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features</article-title>
            <source>Adv. Anat. Pathol.</source>
            <year>2011</year>
            <volume>18</volume>
            <fpage>415</fpage>
            <lpage>437</lpage>
            <pub-id pub-id-type="doi">10.1097/PAP.0b013e318234ab18</pub-id>
            <pub-id pub-id-type="pmid">21993268</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Toyota</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CpG island methylator phenotype in colorectal cancer</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>1999</year>
            <volume>96</volume>
            <fpage>8681</fpage>
            <lpage>8686</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.96.15.8681</pub-id>
            <pub-id pub-id-type="pmid">10411935</pub-id>
            <pub-id pub-id-type="pmcid">PMC17576</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hinoue</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genome-scale analysis of aberrant DNA methylation in colorectal cancer</article-title>
            <source>Genome Res.</source>
            <year>2012</year>
            <volume>22</volume>
            <fpage>271</fpage>
            <lpage>282</lpage>
            <pub-id pub-id-type="doi">10.1101/gr.117523.110</pub-id>
            <pub-id pub-id-type="pmid">21659424</pub-id>
            <pub-id pub-id-type="pmcid">PMC3266034</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Noushmehr</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma</article-title>
            <source>Cancer Cell</source>
            <year>2010</year>
            <volume>17</volume>
            <fpage>510</fpage>
            <lpage>522</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2010.03.017</pub-id>
            <pub-id pub-id-type="pmid">20399149</pub-id>
            <pub-id pub-id-type="pmcid">PMC2872684</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shen</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Olshen</surname>
                <given-names>AB</given-names>
              </name>
              <name name-style="western">
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis</article-title>
            <source>Bioinformatics</source>
            <year>2009</year>
            <volume>25</volume>
            <fpage>2906</fpage>
            <lpage>2912</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btp543</pub-id>
            <pub-id pub-id-type="pmid">19759197</pub-id>
            <pub-id pub-id-type="pmcid">PMC2800366</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hockenbery</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Nunez</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Milliman</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Schreiber</surname>
                <given-names>RD</given-names>
              </name>
              <name name-style="western">
                <surname>Korsmeyer</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death</article-title>
            <source>Nature</source>
            <year>1990</year>
            <volume>348</volume>
            <fpage>334</fpage>
            <lpage>336</lpage>
            <pub-id pub-id-type="doi">10.1038/348334a0</pub-id>
            <pub-id pub-id-type="pmid">2250705</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ciriello</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Cerami</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mutual exclusivity analysis identifies oncogenic network modules</article-title>
            <source>Genome Res.</source>
            <year>2012</year>
            <volume>22</volume>
            <fpage>398</fpage>
            <lpage>406</lpage>
            <pub-id pub-id-type="doi">10.1101/gr.125567.111</pub-id>
            <pub-id pub-id-type="pmid">21908773</pub-id>
            <pub-id pub-id-type="pmcid">PMC3266046</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Mizukami</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Jo</surname>
                <given-names>WS</given-names>
              </name>
              <name name-style="western">
                <surname>Chung</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Oncogenic K-<italic toggle="yes">ras</italic> stimulates Wnt signaling in colon cancer through inhibition of GSK-3β</article-title>
            <source>Gastroenterology</source>
            <year>2005</year>
            <volume>128</volume>
            <fpage>1907</fpage>
            <lpage>1918</lpage>
            <pub-id pub-id-type="doi">10.1053/j.gastro.2005.02.067</pub-id>
            <pub-id pub-id-type="pmid">15940626</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zorn</surname>
                <given-names>AM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Regulation of Wnt signaling by Sox proteins: XSox17 α/β and XSox3 physically interact with β-catenin</article-title>
            <source>Mol. Cell</source>
            <year>1999</year>
            <volume>4</volume>
            <fpage>487</fpage>
            <lpage>498</lpage>
            <pub-id pub-id-type="doi">10.1016/S1097-2765(00)80200-2</pub-id>
            <pub-id pub-id-type="pmid">10549281</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sinner</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sox17 and Sox4 differentially regulate β-catenin/T-cell factor activity and proliferation of colon carcinoma cells</article-title>
            <source>Mol. Cell. Biol.</source>
            <year>2007</year>
            <volume>27</volume>
            <fpage>7802</fpage>
            <lpage>7815</lpage>
            <pub-id pub-id-type="doi">10.1128/MCB.02179-06</pub-id>
            <pub-id pub-id-type="pmid">17875931</pub-id>
            <pub-id pub-id-type="pmcid">PMC2169141</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pollock</surname>
                <given-names>PM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes</article-title>
            <source>Oncogene</source>
            <year>2007</year>
            <volume>26</volume>
            <fpage>7158</fpage>
            <lpage>7162</lpage>
            <pub-id pub-id-type="doi">10.1038/sj.onc.1210529</pub-id>
            <pub-id pub-id-type="pmid">17525745</pub-id>
            <pub-id pub-id-type="pmcid">PMC2871595</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study</article-title>
            <source>Gynecol. Oncol.</source>
            <year>2010</year>
            <volume>116</volume>
            <fpage>15</fpage>
            <lpage>20</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ygyno.2009.09.025</pub-id>
            <pub-id pub-id-type="pmid">19840887</pub-id>
            <pub-id pub-id-type="pmcid">PMC2804260</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vaske</surname>
                <given-names>CJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM</article-title>
            <source>Bioinformatics</source>
            <year>2010</year>
            <volume>26</volume>
            <fpage>i237</fpage>
            <lpage>i245</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btq182</pub-id>
            <pub-id pub-id-type="pmid">20529912</pub-id>
            <pub-id pub-id-type="pmcid">PMC2881367</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32</label>
          <mixed-citation publication-type="other">The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. <italic toggle="yes">Nature</italic><bold>490</bold>, 61–70 (2012)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11412</pub-id><pub-id pub-id-type="pmcid">PMC3465532</pub-id><pub-id pub-id-type="pmid">23000897</pub-id></mixed-citation>
        </ref>
        <ref id="CR33">
          <label>33</label>
          <mixed-citation publication-type="other">The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. <italic toggle="yes">Nature</italic><bold>474</bold>, 609–615 (2011)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10166</pub-id><pub-id pub-id-type="pmcid">PMC3163504</pub-id><pub-id pub-id-type="pmid">21720365</pub-id></mixed-citation>
        </ref>
        <ref id="CR34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Clarke</surname>
                <given-names>BA</given-names>
              </name>
              <name name-style="western">
                <surname>Gilks</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type</article-title>
            <source>J. Clin. Pathol.</source>
            <year>2010</year>
            <volume>63</volume>
            <fpage>410</fpage>
            <lpage>415</lpage>
            <pub-id pub-id-type="doi">10.1136/jcp.2009.071225</pub-id>
            <pub-id pub-id-type="pmid">20418232</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yemelyanova</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases</article-title>
            <source>Am. J. Surg. Pathol.</source>
            <year>2009</year>
            <volume>33</volume>
            <fpage>1504</fpage>
            <lpage>1514</lpage>
            <pub-id pub-id-type="doi">10.1097/PAS.0b013e3181ac35f5</pub-id>
            <pub-id pub-id-type="pmid">19623034</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gilks</surname>
                <given-names>CB</given-names>
              </name>
              <name name-style="western">
                <surname>Oliva</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Soslow</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Poor inter-observer reproducibility in the diagnosis of high-grade endometrial carcinoma</article-title>
            <source>Am. J. Surg. Pathol.</source>
            <year>2012</year>
            <volume>91</volume>
            <fpage>248A</fpage>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0b013e31827f576a</pub-id>
            <pub-id pub-id-type="pmid">23629444</pub-id>
          </element-citation>
        </ref>
        <ref id="CR37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mermel</surname>
                <given-names>CH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</article-title>
            <source>Genome Biol.</source>
            <year>2011</year>
            <volume>12</volume>
            <fpage>R41</fpage>
            <pub-id pub-id-type="doi">10.1186/gb-2011-12-4-r41</pub-id>
            <pub-id pub-id-type="pmid">21527027</pub-id>
            <pub-id pub-id-type="pmcid">PMC3218867</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gaujoux</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Seoighe</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A flexible R package for nonnegative matrix factorization</article-title>
            <source>BMC Bioinformatics</source>
            <year>2010</year>
            <volume>11</volume>
            <fpage>367</fpage>
            <pub-id pub-id-type="doi">10.1186/1471-2105-11-367</pub-id>
            <pub-id pub-id-type="pmid">20598126</pub-id>
            <pub-id pub-id-type="pmcid">PMC2912887</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Houseman</surname>
                <given-names>EA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions</article-title>
            <source>BMC Bioinformatics</source>
            <year>2008</year>
            <volume>9</volume>
            <fpage>365</fpage>
            <pub-id pub-id-type="doi">10.1186/1471-2105-9-365</pub-id>
            <pub-id pub-id-type="pmid">18782434</pub-id>
            <pub-id pub-id-type="pmcid">PMC2553421</pub-id>
          </element-citation>
        </ref>
        <ref id="CR40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brunet</surname>
                <given-names>JP</given-names>
              </name>
              <name name-style="western">
                <surname>Tamayo</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Golub</surname>
                <given-names>TR</given-names>
              </name>
              <name name-style="western">
                <surname>Mesirov</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Metagenes and molecular pattern discovery using matrix factorization</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2004</year>
            <volume>101</volume>
            <fpage>4164</fpage>
            <lpage>4169</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.0308531101</pub-id>
            <pub-id pub-id-type="pmid">15016911</pub-id>
            <pub-id pub-id-type="pmcid">PMC384712</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
